UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

First‐in‐human, randomized dose‐escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF‐06480605 in healthy subjects

British journal of clinical pharmacology, 2020-04, Vol.86 (4), p.812-824

2020

Link zum Volltext

Verfügbarkeit prüfen

A shared tissue transcriptome signature and pathways in psoriasis and ulcerative colitis

Scientific reports, 2022-11, Vol.12 (1), p.19740-19740, Article 19740

2022

Link zum Volltext

Verfügbarkeit prüfen

Quantification of Th1 and Th17 Cells with Intracellular Staining Following PMA/Ionomycin Stimulation

Current Protocols in Cytometry, 2015-01, Vol.71 (1), p.6.35.1-6.35.7

2015

Link zum Volltext

Verfügbarkeit prüfen

Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study

Intestinal research, 2020, 18(1), , pp.45-55

2020

Link zum Volltext

Verfügbarkeit prüfen

Heat Shock Protein-Mediated Cross-Presentation of Exogenous HIV Antigen on HLA Class I and Class II

The Journal of immunology (1950), 2004-08, Vol.173 (3), p.1987-1993

2004

Link zum Volltext

Verfügbarkeit prüfen

Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1

Journal of Crohn's and colitis, 2018-08, Vol.12 (suppl_2), p.S669-S677

2018

Link zum Volltext

Verfügbarkeit prüfen

Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo

Journal of allergy and clinical immunology, 2024-01, Vol.153 (1), p.161-172.e8

2024

Link zum Volltext

Verfügbarkeit prüfen

Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study

Clinical gastroenterology and hepatology, 2023-09, Vol.21 (10), p.2616-2628.e7

2023

Link zum Volltext

Verfügbarkeit prüfen

220 TL1A DRIVES ILC-MEDIATED GRANULOPOIESIS AND COLITIS ASSOCIATED CANCER

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-46-S-46

2024

Link zum Volltext

Verfügbarkeit prüfen

Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study

Clinical gastroenterology and hepatology, 2021-11, Vol.19 (11), p.2324-2332.e6

2021

Link zum Volltext

Verfügbarkeit prüfen

Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis

Inflammatory bowel diseases, 2022-03, Vol.28 (3), p.434-446

2022

Link zum Volltext

Verfügbarkeit prüfen

Tu1863 TRANSCRIPTIONAL AND MICROBIAL BIOMARKERS OF RESPONSE TO ANTI-TL1A THERAPY IN ULCERATIVE COLITIS: THE PHASE 2A TUSCANY STUDY

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-1193-S-1193

2020

Link zum Volltext

Verfügbarkeit prüfen

Rapid synthesis of IFN-gamma by T cells in skin may play a pivotal role in the human skin immune system

International immunology, 1998-11, Vol.10 (11), p.1599-1612

1998

Link zum Volltext

Verfügbarkeit prüfen

Baseline serum and stool microbiome biomarkers predict clinical efficacy and tissue molecular response after ritlecitinib induction therapy in ulcerative colitis

Journal of Crohn's and colitis, 2023-12

2023

Link zum Volltext

Verfügbarkeit prüfen

1027 SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-TL1A ANTIBODY PF-06480605 IN TREATMENT OF ULCERATIVE COLITIS: THE OPEN-LABEL, MULTICENTER, PHASE 2A TUSCANY STUDY

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-206-S-207

2020

Link zum Volltext

Verfügbarkeit prüfen

Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers

Journal of Crohn's and colitis, 2019-05, Vol.13 (6), p.702-713

2019

Link zum Volltext

Verfügbarkeit prüfen

Effect of pf-00547659 on central nervous system immune surveillance and circulating beta 7+t cells in crohn''s disease: report of the tosca study

Journal of Crohn's and colitis, 2018-02, Vol.12, p.188-196

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn’s Disease: Report of the TOSCA Study

Journal of Crohn's and colitis, 2018-01, Vol.12 (2), p.188-196

2018

Link zum Volltext

Verfügbarkeit prüfen

Anti-MAdCAM-1 therapy does not affect immune surveillance in the central nervous system

The Journal of immunology (1950), 2016-05, Vol.196 (1_Supplement), p.139-139.6

2016

Link zum Volltext

Verfügbarkeit prüfen

901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT Study

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-1193-S-1193

2015

Link zum Volltext

Verfügbarkeit prüfen

The TOSCA Study of Immune Surveillance in Cerebrospinal Fluid (CSF) in Crohnʼs Disease (CD) Patients Treated with Anti-MAdCAM Monoclonal Antibody (MAb) PF-00547659: Cohort 1 Clinical Results: 1750

The American journal of gastroenterology, 2013-10, Vol.108, p.S528

2013

Link zum Volltext

Verfügbarkeit prüfen

825 Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA Study

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-162-S-162

2015

Link zum Volltext

Verfügbarkeit prüfen

P-101 Anti-MAdCAM Antibody PF-00547659 in Crohnʼs Disease: Final Efficacy Results From the Open-Label TOSCA Study

Inflammatory bowel diseases, 2014-12, Vol.20, p.S69

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(36)
Dissertationen
(1)

Sprache

Englisch
(37)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(18)
Humans
(16)
Female
(9)
Gastroenterology & Hepatology
(9)
Immunology
(7)
Inflammatory Bowel Disease
(7)
Adult
(5)
Animals
(5)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(5)
Double-Blind Method
(5)
Male
(5)
Middle Aged
(5)
Original
(5)
Severity Of Illness Index
(5)
Ulcerative Colitis
(5)
Clinical Trials
(4)
Dose-Response Relationship, Drug
(4)
Inflammation
(4)
Mice
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

First‐in‐human, randomized dose‐escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF‐06480605 in healthy subjects

A shared tissue transcriptome signature and pathways in psoriasis and ulcerative colitis

Quantification of Th1 and Th17 Cells with Intracellular Staining Following PMA/Ionomycin Stimulation

Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study

Heat Shock Protein-Mediated Cross-Presentation of Exogenous HIV Antigen on HLA Class I and Class II

Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1

Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo

Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study

220 TL1A DRIVES ILC-MEDIATED GRANULOPOIESIS AND COLITIS ASSOCIATED CANCER

Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study

Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis

Tu1863 TRANSCRIPTIONAL AND MICROBIAL BIOMARKERS OF RESPONSE TO ANTI-TL1A THERAPY IN ULCERATIVE COLITIS: THE PHASE 2A TUSCANY STUDY

Rapid synthesis of IFN-gamma by T cells in skin may play a pivotal role in the human skin immune system

Baseline serum and stool microbiome biomarkers predict clinical efficacy and tissue molecular response after ritlecitinib induction therapy in ulcerative colitis

1027 SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-TL1A ANTIBODY PF-06480605 IN TREATMENT OF ULCERATIVE COLITIS: THE OPEN-LABEL, MULTICENTER, PHASE 2A TUSCANY STUDY

Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers

Effect of pf-00547659 on central nervous system immune surveillance and circulating beta 7+t cells in crohn''s disease: report of the tosca study

Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn’s Disease: Report of the TOSCA Study

Anti-MAdCAM-1 therapy does not affect immune surveillance in the central nervous system

901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT Study

The TOSCA Study of Immune Surveillance in Cerebrospinal Fluid (CSF) in Crohnʼs Disease (CD) Patients Treated with Anti-MAdCAM Monoclonal Antibody (MAb) PF-00547659: Cohort 1 Clinical Results: 1750

825 Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA Study

P-101 Anti-MAdCAM Antibody PF-00547659 in Crohnʼs Disease: Final Efficacy Results From the Open-Label TOSCA Study

Suchergebnisse filtern